

(19)



(11)

EP 2 170 157 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

07.09.2016 Bulletin 2016/36

(51) Int Cl.:

A61B 5/00 (2006.01)

(86) International application number:

PCT/US2008/008630

(21) Application number: **08794495.5**

(22) Date of filing: **15.07.2008**

(87) International publication number:

WO 2009/014616 (29.01.2009 Gazette 2009/05)

(54) MEASURING AMOUNT OF BOUND AND COMBINED NITRIC OXIDE IN BLOOD

MESSUNG DER MENGE GEBUNDENEN UND KOMBINIERTEN STICKSTOFFOXIDS IM BLUT

QUANTITÉ DE MESURE D'OXYDE NITRIQUE LIÉ ET COMBINÉ DANS LE SANG

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(56) References cited:

**US-A- 5 174 291 US-A- 5 366 903
US-A- 5 459 076 US-A- 5 891 735
US-A1- 2005 054 908 US-A1- 2006 074 282
US-A1- 2007 149 868**

(30) Priority: **26.07.2007 US 935121 P**

(43) Date of publication of application:

07.04.2010 Bulletin 2010/14

(73) Proprietor: **Duke University**

Durham, NC 27705 (US)

(72) Inventors:

- **STAMLER, Jonathan, S.**
Chapel Hill, NC 27514 (US)
- **ANGELO, Michael**
Durham, NC 27704 (US)

- **YURY VLADIMIROV ET AL: "NO-hemoglobin may be a light-sensitive source of nitric oxide both in solution and in red blood cells", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 59, no. 1-3, 1 December 2000 (2000-12-01), pages 115-122, XP055053252, ISSN: 1011-1344, DOI: 10.1016/S1011-1344(00)00148-2**
- **SONDURR.: 'Metallo Protein Induced Nitric Oxide Release from Nitrosothiols' December 2004, page 20, XP008128929**
- **ALPERT ET AL.: 'Detection of S-Nitrosothiols and other nitric oxide derivatives by photolysis-chemiluminescence spectroscopy' ANAL. BIOCHEM. vol. 245, 1997, pages 1 - 7, XP008128899**

(74) Representative: **Beck Greener**

**Fulwood House
12 Fulwood Place
London WC1V 6HR (GB)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 170 157 B1

Description

Technical Field

[0001] This invention is directed to determining amount of combined nitric oxide in blood. There is a need for this determination in a clinical setting. For example, blood nitric oxide is depressed in patients with sickle cell disease and patients with pulmonary hypertension and determination of this is useful to confirm diagnosis. See Pawloski, J.R., et al., PNAS 102(7), 2531-2536 (2005) and McMahon, T.J., et al. PNAS 102(41), 14801-14806 (10/11/2005). Moreover, blood nitric oxide is elevated in those with sepsis; see Liu, L., et al., Cell 116, 617-628 (2004); and determination of this is useful to confirm diagnosis.

Background of the Invention

[0002] It is known that iron bound nitric oxide and S-nitrosothiols in blood samples degrade and liberate free nitric oxide when the samples are irradiated with ultraviolet (UV) electromagnetic radiation, allowing detection of amount of free nitric oxide.

[0003] In existing machines for detecting amount of nitric oxide bound to hemoglobin and in nitrosothiols in blood, a 150 W mercury vapor lamp is used as a high intensity, broad spectrum UV source that irradiates liquid blood-containing samples as they flow through a Pyrex® glass coil. The use of a 150 W mercury vapor lamp requires a large surface area sample. A flow-through process is necessary to provide the large surface area. A flow-through stream is aerated with a helium carrier gas stream, allowing free nitric oxide gas to be transported to a separate unit that houses a nitric oxide detector where the freed nitric oxide is reacted with ozone to generate light (chemiluminescence) which is detected by a photomultiplier tube. This method is described in Stamler et al. U.S. Patent No. 5,459,076 and in Stamler U.S. Patent No. 5,891,735. This method while useful in a research setting is too cumbersome for a clinical setting. The narrow diameter of the tubing through which the samples pass and elevated temperatures encountered, prohibit measurement on turbid samples in the glass coil of the tubing. Furthermore, the glass coil needs to be reused, requiring cleaning between runs.

[0004] Lucht et al. U.S. Patent No. 6,982,426 teaches a nitric oxide sensor and method comprising passing a signal beam from a laser in a crystal through a sample into a photomultiplier tube and detection of output ultraviolet radiation which indicates level of nitric oxide by comparison with control based on nitric oxide absorption of ultraviolet radiation. Measurements are made by photomultiplier tubes. The apparatus and method are not useful for biological samples and lack sensitivity.

[0005] Sackner et al. U.S. Patent No. 7,090,648 teaches light/laser therapy in wound healing and indicates this

therapy releases nitric oxide from hemoglobin and states that this has the potential to enhance wound healing.

[0006] YURY VLADIMIROV ET AL: "NO-hemoglobin may be a light-sensitive source of nitric oxide both in solution and in red blood cells", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 59, no. 1-3, 1 December 2000, pages 115-122 discloses EPR detection of free nitric oxide produced as a result of photolysis of the nitrosyl complex of haemoglobin by means of a spin trap, nitronyl nitroxyl radical.

Summary of the Invention

[0007] It has been discovered herein that use of a low power laser electromagnetic radiation beam or of a low power light-emitting diode electromagnetic radiation to liberate nitric oxide gas from a blood sample, allows use on a stationary small volume, small surface area sample which may constitute whole cells and use of a disposable sample container. As used herein the term "low power" means less than 100 milliwatts, e.g. 30 to 60 milliwatts, e.g. 50 milliwatts.

[0008] A first embodiment herein is directed at a method for liberating nitric oxide gas from nitric oxide present as iron nitrosyls and as nitrosothiols in a blood sample, comprising the steps of:

- (a) introducing the blood sample into a sample containing zone having a front side which is electromagnetic radiation transparent and a rear side which is porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;
- (b) directing electromagnetic radiation of less than 100 milliwatts at said front side to cause liberation of nitric oxide gas from iron nitrosyls and as nitrosothiols and passage of the liberated nitric oxide gas from said rear side;
- (c) providing a solvent containing zone to dissolve the liberated nitric oxide gas that has passed through said rear side where the solvent is one that dissolves nitric oxide gas;
- (d) electrochemically detecting the amount of dissolved nitric oxide gas in the solvent which corresponds to the total amount of nitric oxide present as iron nitrosyls and as nitrosothiols in the sample.

[0009] Preferably, the blood sample is untreated.

[0010] A second embodiment herein is directed at a method for liberating nitric oxide gas from nitric oxide present as iron nitrosyls in a blood sample which has been treated with a nitrosothiol degrading agent to degrade nitrosothiols in the sample to nitrous acid, comprising the steps of:

- (a) introducing the blood sample into a sample containing zone having a front side which is electromagnetic radiation transparent and a rear side which is

porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;

(b) directing electromagnetic radiation of less than 100 milliwatts at said front side to cause liberation of nitric oxide gas from iron nitrosyls and passage of the liberated nitric oxide gas from said rear side;

(c) providing a solvent containing zone to dissolve the liberated nitric oxide gas that has passed through said rear side where the solvent is one that dissolves nitric oxide gas;

(d) electrochemically detecting the amount of dissolved nitric oxide gas in the solvent which corresponds to the total amount of nitric oxide present as iron nitrosyls in the sample.

[0011] In a preferred embodiment, the method is for determining the amount of nitric oxide present as nitrosothiols and also the amount of nitric oxide present as iron nitrosyls and the method comprises:

(i) obtaining two samples of blood from the same source;

(ii) treating the one sample with a nitrosothiols degrading agent to cause decomposition of nitrosothiols to nitrous acid and leaving iron nitrosyls in the sample and leaving the other sample untreated with a nitrosothiols degrading agent;

(iii) separately subjecting both the treated and untreated samples to analysis by steps (a) to (d) set out above.

[0012] A third embodiment herein is directed at an apparatus for conducting a method described above comprising:

a blood sample containing zone having a front side which is electromagnetic radiation transparent and a rear side which is porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;

a low power electromagnetic radiation emitter for directing said radiation at said front side;

a solvent containing zone to receive for dissolution in the solvent the liberated nitric oxide gas that passes through said rear side; and

a nitric oxide electrode for detecting voltage generated by the presence of nitric oxide in the solvent.

[0013] Preferably, there are two blood containing zones each with a respective solvent containing zone.

Brief Description of the Drawings

[0014]

Figure 1 depicts a disposable phlebotomy cassette for holding the first sample and treated second sam-

ple of the method for determining the amount of nitric oxide present as nitrosothiols and also the amount of nitric oxide present as iron nitrosyls described above;

Figure 2 depicts a reusable housing for holding solvent and for insertion of electrode, for use in association with the cassette of Figure 1;

Figure 3 depicts an assembly of the cassette of Figure 1 and the housing of Figure 2;

Figure 4 is an exploded view of the assembly of Figure 3 showing some interior details;

Figure 5 is a schematic of apparatus for the method for determining the amount of nitric oxide present as nitrosothiols and also the amount of nitric oxide present as iron nitrosyls described above.

Detailed Description

[0015] A low power radiation emitter is used in all embodiments herein because it has been found that such a radiation emitter can be used to deliver a large dose of radiation to a stationary small sample of blood to liberate nitric oxide gas therefrom. The dose of energy delivered by the emitter is proportional to the power of the emitter and inversely proportional to the diameter of the emitter beam.

[0016] The low power electromagnetic radiation can preferably be ultraviolet radiation having a wavelength ranging from 300 to 400 nm, very preferably from 325 to 355 nm. This can be provided by a low power ultraviolet laser especially a neodymium-doped yttrium aluminum garnet laser, i.e. a Nd:Y₃Al₅O₁₂ laser, which emits ultraviolet radiation or by a tunable laser tuned, e.g. to provide 325 to 355 nm radiation, commercially available from Optronix, Inc. (California) in the specified range. This low power ultraviolet radiation can also be provided by an ultraviolet light-emitting diode which is commercially available to emit ultraviolet radiation in these wavelengths.

[0017] The low power electromagnetic radiation can also be ultraviolet radiation having a wavelength ranging from 210 to 220 nm, e.g. 220 nm. Light-emitting diodes emitting ultraviolet radiation down to 210 nm wavelength are available, e.g. aluminum gallium indium nitride light emitting diodes emitting down to 210 nm wavelength are available.

[0018] The low power electromagnetic radiation can also be low power visible electromagnetic radiation having a wavelength ranging from 500 to 600 nm. This can be provided by a low power green LED lamp which is commercially available.

[0019] The low power electromagnetic radiation can also be low power near infrared radiation (700-1400 nm wavelength). This can be provided by a near-infrared light-emitting diode which is commercially available.

[0020] The 210-220 nm, 300-400, 500-600 nm and near-infrared wavelength emissions referred to above degrade nitrosothiols to gaseous nitric oxide and to pro-

vide adequate absorbance into iron nitrosyls (characteristic moiety for nitric oxide bound to heme) to liberate gaseous nitric oxide therefrom.

[0021] We turn now to the blood sample. It has a small surface area and small volume. For example, it can have a diameter ranging, for example, from 2 to 6 mm with a transverse dimension of, for example, 0.5 to 1 mm.

[0022] The blood sample is readily obtained by pricking a finger with a sharp and may be loaded into a sample holder by capillary action.

[0023] If it is only desired to liberate nitric oxide from iron nitrosyls in blood, the blood sample is treated with metal ion (e.g., mercury (II) ion or Ag^+ ion), e.g. mercury chloride, or organic mercury (e.g., methyl mercury) to degrade nitrosothiols in the sample to nitrous acid (which does not liberate nitric oxide on receiving electromagnetic radiation energy). This can be carried out by providing nitrosothiol degrading agent in a sample containing (holding) zone before loading of blood sample therein. In this case the radiation emitter is directed at the blood sample which has been treated to degrade nitrosothiol and the term "blood sample" includes untreated blood sample as well as nitrosothiols degraded treated (treated with nitrosothiols degrading agent) blood sample.

[0024] A laser or light-emitting diode is positioned, e.g., up to a foot (0.3 m), for example, 6 to 10 inches (15 to 25 cm) from the sample. This distance can be reduced if fiber optic transmission of emitter beam is utilized.

[0025] An electromagnetic radiation beam is directed at the sample and preferably on reaching the sample, has a cross-sectional area the same as and coextensive with the cross-sectional area of the sample.

[0026] The electromagnetic radiation treatment causes photolysis of nitrosothiols and iron nitrosyls in a blood sample or a treated blood sample to release gaseous nitric oxide and is continued until nitric oxide gas emission is no longer noted.

[0027] The front side (wall) of the sample containing zone is electromagnetic radiation transparent so the front wall of the sample containing zone does not cause attenuation of radiation energy emitting to the front side of the samples, i.e. transmits at least approximately 95% of the radiation energy directed thereat.

[0028] The front side of the sample holding zone can be, for example, Vycor® glass (Corning Glass Works), or quartz.

[0029] The rear side of the sample containing zone is preferably of a material of construction which is porous to the extent of permitting passage of nitric oxide gas but not to the extent of permitting passage of protein, e.g., 40 micron pores, so as to separate liberated nitric oxide gas from protein so liberated nitric oxide gas cannot recombine with protein. The rear side of the sample containing zone is preferably of Vycor® glass.

[0030] The solvent containing zone except adjacent the rear side gas passage permitting portion of the sample holding zone, is constructed of an inert material, e.g. polytetrafluoroethylene and is preferably painted black

except adjacent where nitric oxide gas is passing from the sample container (as explained later).

[0031] The solvent in the solvent containing zone is one that has a higher solubility for nitric oxide gas than the sample and is preferably methanol.

[0032] The electrochemical detection is with nitric oxide selective electrode which is an ion selective electrode that generates a small voltage (e.g., in the picovolt range) which is quantitatively proportional to this concentration of nitric oxide dissolved in solvent when immersed in the solvent with nitric oxide dissolved therein.

[0033] We turn now to calibration of the response provided by the electrode with amount of nitric oxide gas released and dissolved in the solvent. Nitrosoglutathione can be used to calibrate for photolysis of amount of nitric oxide from nitrosothiols and sodium nitroprusside can be used to calibrate for photolysis of amount of nitric oxide from iron nitrosyls and both cover the range of amounts of nitric oxide from the combined nitric oxide. Nitric oxide selective electrodes are commercially available.

[0034] In a preferred method, the blood sample is loaded into the sample containing zone with and/or without nitrosothiol degrading agent therein, e.g. by pricking a finger with a lancet or other sharp and loading the sample into the sample containing zone, for example, by capillary action, solvent is introduced into a solvent containing zone, the rear side of the sample containing zone is positioned adjacent the solvent containing zone, followed by positioning a low power electromagnetic radiation emitter (low power laser or low power light-emitting diode) up to 12 inches (0.3 m) away from the sample containing zone and irradiating sample in the sample containing zone with the electromagnetic radiation emitter emitting a beam of cross-sectional area corresponding to the cross-sectional area of the sample. The electrode is lowered into the solvent containing zone and detects a generated voltage corresponding to the amount of nitric oxide in the solvent containing zone. Electromagnetic radiation beam is directed at the sample for as long as nitric oxide gas increase is detected, whereupon the electromagnetic radiation source is turned off and the electrode is raised out of contact with the solvent whereupon apparatus providing the sample containing zone may be discarded.

[0035] The generated voltage detected by the electrode is in the picovolt range and is amplified using a DC amplifier for measurement, e.g., using a voltmeter. A signal integrator can be present in the system to quantify the area under any peak. Signal from the amplifier and/or signal integrator may feed into an analog to digital converter which passes a signal to a computer or volt meter or other digital interface to provide digital or graphical readout indicating amount of combined nitric oxide, that is total nitric oxide present as nitrosothiols and iron nitrosyls (no nitrosothiol destroying agent used), or amount of nitric oxide present as iron nitrosyls (nitrosothiol destroying agent used).

[0036] The front side of the sample containing zone is

transparent to whichever electromagnetic radiation is emitted in the direction of the sample containing zone to allow passing of the electromagnetic radiation into the sample containing zone and cause liberation of nitric oxide from the sample.

[0037] A preferred system for carrying out the method for determining the amount of nitric oxide present as nitrosothiols and also the amount of nitric oxide present as iron nitrosyls is depicted in Figures 1-5.

[0038] With reference to Figure 1, there is schematically depicted a disposable phlebotomy cassette 10 which contains blood sample containing chambers 12 and 14 which both constitute sample containing zones. A front wall 16 of cassette 10 is of Vycor® glass or other electromagnetic radiation transparent material (i.e. to whichever kind of electromagnetic radiation is used) and a rear wall 18 of the cassette is constituted, for example, of Vycor® glass (40 micron pores) and reliance is placed on the rear wall's property of being porous to nitric oxide gas but preventing passage therethrough of protein. The blood sample containing chamber 12 is impregnated with mercury (II) chloride or other nitrosothiols destroying agent so as not to interfere with absorption of electromagnetic radiation by blood sample. Blood sample containing chambers 12 and 14 are, for example, 4 mm diameter and 5 mm transverse dimension. The chamber 12 contains nitrosothiols destroying agent, e.g. mercury (II) chloride, in large excess, compared to nitrosothiols that are present; the chamber 14 does not contain nitrosothiols destroying agent.

[0039] Communicating with chamber 12 is a capillary blood sample containing chamber/zone inlet 20. Communicating with chamber 14 is a capillary blood sample containing chamber/zone inlet 22.

[0040] With reference to Figure 2, there is schematically depicted a reusable solvent reservoir/electrode introduction compartment or housing 24 which provides a solvent containing zone and which is constructed of inert material (i.e., inert to solvent and nitric oxide gas), e.g. polytetrafluoroethylene. The element 24 contains two solvent reservoir compartments 26 and 28 separated by a partition 30. The element 24 contains a solid back wall and a front wall with circular openings 32 and 34, respectively, into each of the compartments 26 and 28. The opening 32 is bounded by a ring shaped upstanding protruding wall 36, and the opening 34 is bounded by ring shaped upstanding protruding wall 38. An upper wall of element 24 is provided with an opening 40 for introduction of an electrode into compartment 26 and an opening 42 for introduction of electrode into compartment 28. Each of the upstanding walls 36 and 38 is colored black or otherwise provided with electromagnetic radiation shielding to minimize and guard against electromagnetic radiation scattering to inserted electrode (described later) since electromagnetic radiation affects the voltage detected by an electrode.

[0041] The disposable cassette 10 and solvent reservoir/electrode introduction compartment 24 are assem-

bled, for example, by clamping cassette 10 to solvent reservoir/electrode introduction compartment 24 so the rear side of cassette 10 adjacent chambers 12 and 14 is contiguous with openings 32 and 34 (Figure 2). Alternatively, cassette 10 can be attached to element 24 by providing retaining brackets on the front side of element 24 or by providing structure on the front of element 24 providing an insertion slot for assembling cassette 10 and element 24. The assembly provided is schematically depicted in Figure 3 which is denoted 58.

[0042] Figure 4 depicts an exploded view of the assembly of Figure 3, and indicates the cassette 10 positioned in front of a front wall 44 of element 24. The front wall 44 is forward of rear wall 46 of element 24. Element 44 contains a left side wall 48, a right side wall 50, an interior vertical wall 52 dividing element 24 into compartments 26 and 28 (depicted in Figure 2), a bottom wall 54 and a top wall 56 containing electrode insertion openings 40 and 42 (also depicted in Figure 2).

[0043] Figure 5 depicts phlebotomy cassette 10 (see also Figure 1), solvent reservoir/electrode introduction compartment 24 (see also Figure 2), assembly 58 (see also Figure 3) as well as an electromagnetic radiation source depicted as a laser source 60 which directs a laser beam 62 of 325-355 nm frequency and 50 milliwatts power, e.g. a Nd:Y₃A₁₅O₁₂ laser, at one of the sample containing compartments 12 and 14, from a distance, for example, of 6 to 10 inches (15 to 25 cm), providing a laser beam of cross-sectional area at assembly 58 co-extensive with the inlet opening of a sample containing compartment (12 or 14) to which it is directed.

[0044] Also depicted in Figure 5 is a nitric oxide selective electrode 64 provided with a vertical actuator (not shown) which can be operated by a computer to raise or lower the electrode 64 into the appropriate electrode insertion opening (40 or 42). The electrode 64 is shown inserted into compartment 26 (Figure 2) at 65 (Figure 5).

[0045] The electrode 64 is a nitric oxide selective electrode detecting voltage generated by presence of nitric oxide gas in solvent in 24 and providing a signal 66 in picovolts to a DC amplifier 68 which in turn provides an amplified signal to a signal integrator and to a graphic readout device 70 which provides readout of amount of nitric oxide dissolved in solvent corresponding to amount of nitric oxide present as combined nitric oxide.

[0046] In use, finger of patient for whom blood nitric oxide data is desired, is pricked with a lancet, e.g. at bedside, to provide blood flow by capillary action through channels 20 and 22 respectively into chambers 12 and 14 (Figure 1). Then element 24 (Figure 2) laid flat with rings 36 and 38 facing up, is filled through openings 32 and 34 with solvent that is of higher solubility for nitric oxide gas than the blood sample, preferably methanol. 1. The cassette 10 is then assembled with element 24 so compartments 12 and 14 are opposite openings 32 and 34 respectively, e.g. by clamping cassette 10 to element 24 so that windows for compartments 12 and 14 are in front of the cassette 10. Then laser 60 (Figure 5)

is turned on to provide beam of ultraviolet laser irradiation of 325 - 355 nm of intensity high enough to maximize nitric oxide that is liberated (i.e. is the intensity sufficient to break bonds to nitric oxide) but not so large as to break down or otherwise interfere with providing liberated nitric oxide) into compartment 12 or compartment 14, e.g. 50 milliwatts power. Electrode 64 (Figure 5) is lowered into solvent reservoir 26 after the laser beam of laser 60 is directed at sample compartment 12 and raised from compartment 12 after electrochemical detection of released nitric oxide, and lowered into solvent reservoir 28 after the laser beam of laser 60 is directed at sample compartment 14 and raised from compartment 14 after electrochemical detection of released nitric oxide. The raising and lowering of electrode 64 into compartments 26 and 28 is preferably by computer activation of driving motor (not shown). Separate measurements are obtained in succession in either order.

[0047] The nitrosothiol destroying agent in compartment 12 degrades (selectively cleaves) the nitrosothiols therein to nitrous acid from which nitric oxide is not liberated by electromagnetic radiation.

[0048] When the laser beam 62 is aimed at compartment 12, electrode 64 is lowered through opening 40 into solvent compartment 26. The laser treatment liberates gaseous nitric oxide from iron nitrosyls in the sample in compartment 12 which passes from compartment 12 to diffuse through the porous back wall of cassette 10 into compartment 26 where the liberated nitric oxide is dissolved in the solvent in chamber 26. Laser irradiation is continued for as long as reading on readout at 70 increases. The readout indicates the amount of nitric oxide present as iron nitrosyls in the sample.

[0049] When the laser beam 62 is aimed at compartment 14, electrode 64 is lowered through opening 42 into solvent compartment 28. The laser treatment liberates nitric oxide from iron nitrosyls and also from nitrosothiols. The liberated nitric oxide passes through the porous back wall of cassette 10 into solvent reservoir 28 whereby amount of dissolved nitric oxide is detected to provide readout at 70 of total nitric oxide present as combined nitric oxide.

[0050] The porous back wall of cassette 10 allows passage of nitric oxide gas into solvent containing zones but no protein so irradiation causes continuous release of nitric oxide without any rebinding to protein.

[0051] The determination of total nitric oxide present as combined nitric oxide and of nitric oxide present as iron nitrosyls allows computation of ratio of nitric oxide present as iron nitrosyls to total nitric oxide, i.e. present as combined nitric oxide, and by difference determination of amount of nitrosothiols in a sample thereby providing data allowing diagnosis and/or confirmation of diagnosis.

[0052] The laser 60 can be replaced by a light-emitting diode that emits 210-220 nm wavelength ultraviolet radiation or 300-400 nm wavelength ultraviolet radiation or 500-600 nm wavelength visible radiation or 700-1400 nm wavelength near-infrared radiation with excellently com-

parable results.

Variations

- [0053]** The foregoing description of the invention has been presented describing certain operable and preferred embodiments. It is not intended that the invention should be so limited since variations and modifications thereof will be obvious to the skilled in the art, all of which are within the scope of the invention as defined by the following claims.

Claims

1. A method for liberating nitric oxide gas from nitric oxide present as iron nitrosyls and as nitrosothiols in a blood sample, comprising the steps of:
 - (a) introducing the blood sample into a sample containing zone (12) having a front side (16) which is electromagnetic radiation transparent and a rear side (18) which is porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;
 - (b) directing electromagnetic radiation of less than 100 milliwatts at said front side (16) to cause liberation of nitric oxide gas from iron nitrosyls and nitrosothiols and passage of the liberated nitric oxide gas from said rear side (18);
 - (c) providing a solvent containing zone (24) to dissolve the liberated nitric oxide gas that has passed through said rear side (18) where the solvent is one that dissolves nitric oxide gas;
 - (d) electrochemically detecting the amount of dissolved nitric oxide gas in the solvent which corresponds to the total amount of nitric oxide present as iron nitrosyls and as nitrosothiols in the sample.
2. A method of claim 1 where the blood sample is untreated.
3. A method for liberating nitric oxide gas from nitric oxide present as iron nitrosyls in a blood sample which has been treated with a nitrosothiol degrading agent to degrade nitrosothiols in the sample to nitrous acid, comprising the steps of:
 - (a) introducing the blood sample into a sample containing zone (12) having a front side (16) which is electromagnetic radiation transparent and a rear side (18) which is porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;
 - (b) directing electromagnetic radiation of less

- than 100 milliwatts at said front side (16) to cause liberation of nitric oxide gas from iron nitrosyls and passage of the liberated nitric oxide gas from said rear side (18);
- (c) providing a solvent containing zone (24) to dissolve the liberated nitric oxide gas that has passed through said rear side (18) where the solvent is one that dissolves nitric oxide gas;
- (d) electrochemically detecting the amount of dissolved nitric oxide gas in the solvent which corresponds to the total amount of nitric oxide present as iron nitrosyls in the sample.
4. A method of claim 1 for determining the amount of nitric oxide present as nitrosothiols and also the amount of nitric oxide present as iron nitrosyls comprising:
- (i) obtaining two samples of blood from the same source;
- (ii) treating the one sample with a nitrosothiols degrading agent to cause decomposition of nitrosothiols to nitrous acid and leaving iron nitrosyls in the sample and leaving the other sample untreated with a nitrosothiols degrading agent;
- (iii) separately subjecting both the treated and untreated samples to analysis by steps (a) to (d) of claim 1.
5. A method of claim 1 or claim 4 where the solvent in step (c) is methanol.
6. A method of any one of the preceding claims where the electromagnetic radiation is ultraviolet radiation.
7. A method of any one of claims 1 to 5 where the low power electromagnetic radiation is visible electromagnetic radiation having a wavelength ranging from 500 to 600 nm.
8. A method of any one of claims 1 to 5 where the electromagnetic radiation is near-infrared radiation.
9. A method of any one of claims 1 to 5 where the electromagnetic radiation is from a laser (60).
10. A method of any one of claims 1 to 5 where the electromagnetic radiation is from a light-emitting diode.
11. A method of claim 6 where the ultraviolet radiation has a wavelength ranging from 300 to 400 nm.
12. The method of claim 6 where the ultraviolet radiation has a wavelength ranging from 210 to 220 nm.
13. An apparatus for conducting a method of Claim 1 comprising:

a blood sample containing zone (12) having a front side (16) which is electromagnetic radiation transparent and a rear side (18) which is porous to the extent of permitting nitric oxide gas to pass therethrough while preventing protein from passing therethrough;

a electromagnetic radiation emitter (60) for directing electromagnetic radiation of less than 100 milliwatts at said front side;

a solvent containing zone (24) to receive for dissolution in the solvent the liberated nitric oxide gas that passes through said rear side; and

a nitric oxide electrode (64) for detecting voltage generated by the presence of nitric oxide in the solvent.

14. An apparatus of claim 13 where there are two blood containing zones (12 and 14) each with a respective solvent containing zone (26 and 28).

Patentansprüche

1. Ein Verfahren für das Befreien von Stickstoffmonoxidgas aus als Eisennitrosyle und als Nitrosothiole in einer Blutprobe vorhandenem Stickstoffmonoxid, umfassend folgende Schritte:
- (a) Einführen der Blutprobe in eine Proben enthaltende Zone (12) mit einer Vorderseite (16), welche durchlässig für elektromagnetische Strahlung ist, und mit einer Rückseite (18), welche so weit porös ist, dass Stickstoffmonoxidgas sie passieren kann, während sie Protein daran hindert, sie zu passieren;
- (b) Richten einer elektromagnetischen Strahlung von weniger als 100 Milliwatt auf die genannte Vorderseite (16), um die Befreiung des Stickstoffmonoxidgases aus den Eisennitrosylen und Nitrosothiolen und das Passieren des befreiten Stickstoffmonoxidgases durch die genannte Rückseite (18) zu bewirken;
- (c) Vorsehen einer Lösungsmittel enthaltenden Zone (24), um das befreite Stickstoffmonoxidgas aufzulösen, welches die genannte Rückseite (18) passiert hat, wobei das Lösungsmittel ein solches ist, das Stickstoffmonoxidgas auflöst;
- (d) elektrochemisches Bestimmen der Menge des aufgelösten Stickstoffmonoxidgases in dem Lösungsmittel, welche der Gesamtmenge des als Eisennitrosyle und als Nitrosothiole in der Probe enthaltenen Stickstoffmonoxids entspricht.
2. Verfahren von Anspruch 1, bei welchem die Blutprobe unbehandelt ist.
3. Verfahren für das Befreien von Stickstoffmonoxid-

gas aus Stickstoffmonoxid, welches als Eisennitrosyle in einer Blutprobe vorhanden ist, die mit einem Nitrosothiol abbauenden Wirkstoff behandelt worden ist, um die Nitrosothiole in der Probe zu salpetriger Säure abzubauen, umfassend folgende Schritte:

- (a) Einführen der Blutprobe in eine Proben enthaltende Zone (12) mit einer Vorderseite (16), welche durchlässig für elektromagnetische Strahlung ist, und mit einer Rückseite (18), welche so weit porös ist, dass Stickstoffmonoxidgas sie passieren kann, während sie Protein daran hindert, sie zu passieren;
 - (b) Richten einer elektromagnetischen Strahlung von weniger als 100 Milliwatt auf die genannte Vorderseite (16), um die Befreiung des Stickstoffmonoxidgases aus den Eisennitrosylen und das Passieren der genannten Rückseite (18) durch das befreite Stickstoffmonoxidgas zu bewirken;
 - (c) Vorsehen einer Lösungsmittel enthaltenden Zone (24), um das befreite Stickstoffmonoxidgas aufzulösen, welches die genannte Rückseite (18) passiert hat, wobei das Lösungsmittel ein solches ist, das Stickstoffmonoxidgas auflöst;
 - (d) elektrochemisches Detektieren der Menge des aufgelösten Stickstoffmonoxidgases in dem Lösungsmittel, welche der Gesamtmenge des als Eisennitrosyle in der Probe enthaltenen Stickstoffmonoxids entspricht.
4. Verfahren von Anspruch 1 für das Bestimmen der Menge des als Nitrosothiole vorhandenen Stickstoffmonoxids und auch der Menge des als Eisennitrosyle vorhandenen Stickstoffmonoxids, umfassend:
- (i) Entnehmen von zwei Blutproben aus derselben Quelle;
 - (ii) Behandeln der einen Probe mit einem Nitrosothiole abbauenden Wirkstoff, um den Zerfall von Nitrosothiolen zu salpetriger Säure zu verursachen, und Belassen von Eisennitrosylen in der Probe, und das Nichtbehandeln der anderen Probe mit einem Nitrosothiole abbauenden Wirkstoff;
 - (iii) separates Unterziehen sowohl der behandelten Probe als auch der unbehandelten Probe einer Analyse durch die Schritte (a) bis (d) von Anspruch 1.
5. Verfahren von Anspruch 1 oder Anspruch 4, bei welchem das Lösungsmittel in Schritt (c) Methanol ist.
6. Verfahren eines beliebigen der vorhergehenden Ansprüche, bei welchem die elektromagnetische Strahlung Ultraviolettstrahlung ist.

7. Verfahren eines beliebigen der Ansprüche 1 bis 5, bei welchem die elektromagnetische Niedrigenergiestrahlung eine sichtbare elektromagnetische Strahlung mit einer von 500 bis 600 nm reichenden Wellenlänge ist.
8. Verfahren eines beliebigen der Ansprüche 1 bis 5, bei welchem die elektromagnetische Strahlung Nahinfrarotstrahlung ist.
9. Verfahren eines beliebigen der Ansprüche 1 bis 5, bei welchem die elektromagnetische Strahlung aus einem Laser (60) kommt.
10. Verfahren eines beliebigen der Ansprüche 1 bis 5, bei welchem die elektromagnetische Strahlung aus einer Leuchtdiode (LED) kommt.
11. Verfahren von Anspruch 6, bei welchem die Ultraviolettstrahlung eine von 300 bis 400 nm reichende Wellenlänge hat.
12. Das Verfahren von Anspruch 6, bei welchem die Ultraviolettstrahlung eine von 210 bis 220 nm reichende Wellenlänge hat.
13. Eine Vorrichtung für das Durchführen eines Verfahrens nach Anspruch 1, umfassend: eine Blutproben enthaltende Zone (12) mit einer Vorderseite (16), welche durchlässig für elektromagnetische Strahlung ist, und mit einer Rückseite (18), welche so weit porös ist, dass Stickstoffmonoxidgas sie passieren kann, während sie Protein daran hindert, sie zu passieren; eine elektromagnetische Strahlungsquelle (60), um die elektromagnetische Strahlung von weniger als 100 Milliwatt auf die genannte Vorderseite zu richten; eine Lösungsmittel enthaltenden Zone (24), um das befreite Stickstoffmonoxidgas, welches die genannte Rückseite passiert, zur Auflösung im Lösungsmittel aufzunehmen, sowie eine Stickstoffmonoxid-Elektrode (64) für das Detektieren einer durch das Vorhandensein von Stickstoffmonoxid in dem Lösungsmittel erzeugten Spannung.
14. Vorrichtung von Anspruch 13, bei welcher zwei Blut enthaltende Zonen (12 und 14), jede von ihnen mit einer jeweiligen Lösungsmittel enthaltenden Zone (26 und 28), vorhanden sind.

Revendications

1. Méthode de libération de gaz d'oxyde nitrique d'oxyde nitrique présent sous forme de complexe fer-nitrosyles et de nitrosothiols dans un échantillon de sang, comprenant les étapes consistant à :

- (a) introduire l'échantillon de sang dans une zone de contenance (12) d'échantillon comportant un côté avant (16) qui est transparent à un rayonnement électromagnétique et un côté arrière (18) qui est poreux dans la mesure permettant à du gaz d'oxyde nitrique de le traverser tout en empêchant le passage d'une protéine à travers ce dernier ;
- (b) diriger un rayonnement électromagnétique de moins de 100 milliwatts au niveau dudit côté avant (16) de façon à provoquer une libération de gaz d'oxyde nitrique de complexe fer-nitrosyles et de nitrosothiols et un passage du gaz d'oxyde nitrique libéré à partir dudit côté arrière (18) ;
- (c) établir une zone de contenance (24) de solvant servant à dissoudre le gaz d'oxyde nitrique libéré qui a traversé ledit côté arrière (18), dans laquelle le solvant est du type qui dissout le gaz d'oxyde nitrique ;
- (d) détecter par réaction électrochimique la quantité de gaz d'oxyde nitrique dissout dans le solvant qui correspond à la quantité totale d'oxyde nitrique présent sous forme de complexe fer-nitrosyles et de nitrosothiols dans l'échantillon.
2. Méthode selon la revendication 1, dans laquelle l'échantillon de sang n'est pas traité.
3. Méthode de libération de gaz d'oxyde nitrique d'oxyde nitrique présent sous forme de complexe fer-nitrosyles dans un échantillon de sang qui a été traité avec un agent de dégradation de nitrosothiols de façon à dégrader les nitrosothiols de l'échantillon en acide nitreux, comprenant les étapes consistant à :
- (a) introduire l'échantillon de sang dans une zone de contenance (12) d'échantillon comportant un côté avant (16) qui est transparent à un rayonnement électromagnétique et un côté arrière (18) qui est poreux dans la mesure permettant à du gaz d'oxyde nitrique de le traverser tout en empêchant le passage d'une protéine à travers ce dernier ;
- (b) diriger un rayonnement électromagnétique de moins de 100 milliwatts au niveau dudit côté avant (16) de façon à provoquer une libération de gaz d'oxyde nitrique de complexe fer-nitrosyles et un passage du gaz d'oxyde nitrique libéré à partir dudit côté arrière (18) ;
- (c) établir une zone de contenance (24) de solvant servant à dissoudre le gaz d'oxyde nitrique libéré qui a traversé ledit côté arrière (18), dans laquelle le solvant est du type qui dissout le gaz d'oxyde nitrique ;
- (d) détecter par réaction électrochimique la quantité de gaz d'oxyde nitrique dissout dans le solvant qui correspond à la quantité totale d'oxyde nitrique présent sous forme de complexe fer-nitrosyles dans l'échantillon.
4. Méthode selon la revendication 1, permettant de déterminer la quantité d'oxyde nitrique présent sous forme de nitrosothiols et également la quantité d'oxyde nitrique présent sous forme de complexe fer-nitrosyles, consistant à :
- (i) obtenir deux échantillons de sang de la même source ;
- (ii) traiter le premier échantillon avec un agent de dégradation de nitrosothiols de façon à provoquer une décomposition de nitrosothiols en acide nitreux et à laisser le complexe fer-nitrosyles dans l'échantillon et laisser l'autre échantillon non traité avec un agent de dégradation de nitrosothiols ;
- (iii) soumettre séparément les deux échantillons traité et non traité à une analyse selon les étapes (a) à (d) de la revendication 1.
5. Méthode selon la revendication 1 ou la revendication 4, dans laquelle le solvant de l'étape (c) est du méthanol.
6. Méthode selon l'une quelconque des revendications précédentes, dans laquelle le rayonnement électromagnétique est un rayonnement ultraviolet.
7. Méthode selon l'une quelconque des revendications 1 à 5, dans laquelle le rayonnement électromagnétique de faible puissance est un rayonnement électromagnétique visible ayant une longueur d'onde allant de 500 à 600 nm.
8. Méthode selon l'une quelconque des revendications 1 à 5, dans laquelle le rayonnement électromagnétique est un rayonnement dans le proche infrarouge.
9. Méthode selon l'une quelconque des revendications 1 à 5, dans laquelle le rayonnement électromagnétique est issu d'un laser (60).
10. Méthode selon l'une quelconque des revendications 1 à 5, dans laquelle le rayonnement électromagnétique est issu d'une diode électroluminescente.
11. Méthode selon la revendication 6, dans laquelle le rayonnement ultraviolet a une longueur d'onde allant de 300 à 400 nm.
12. Méthode selon la revendication 6, dans laquelle le rayonnement ultraviolet a une longueur d'onde allant de 210 à 220 nm.
13. Appareil de mise en oeuvre d'une méthode selon la revendication 1, comprenant :

une zone de contenance (12) d'échantillon de sang comportant un côté avant (16) qui est transparent à un rayonnement électromagnétique et un côté arrière (18) qui est poreux dans la mesure permettant à du gaz d'oxyde nitrique de le traverser tout en empêchant le passage d'une protéine à travers ce dernier ;

5

un émetteur de rayonnement électromagnétique (60) servant à diriger un rayonnement électromagnétique de moins de 100 milliwatts au niveau dudit côté avant ;
une zone de contenance (24) de solvant servant à recevoir, à des fins de dissolution dans le solvant, le gaz d'oxyde nitrique libéré qui traverse ledit côté arrière ; et
une électrode (64) d'oxyde nitrique servant à détecter une tension générée par la présence d'oxyde nitrique dans le solvant.

10

15

20

14. Appareil selon la revendication 13, dans lequel on trouve deux zones de contenance (12 et 14) de sang comportant chacune une zone de contenance respective (26 et 28) de solvant.

25

30

35

40

45

50

55




FIG. 1




FIG. 2

ASSEMBLED
CASSETTE AND
HOUSING




FIG. 3




FIG. 4




FIG. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5459076 A, Stamler [0003]
- US 5891735 A, Stamler [0003]
- US 6982426 B, Lucht [0004]
- US 7090648 B, Sackner [0005]

Non-patent literature cited in the description

- **PAWLOSKI, J.R. et al.** *PNAS*, 2005, vol. 102 (7), 2531-2536 [0001]
- **MCMAHON, T.J. et al.** *PNAS*, 11 October 2005, vol. 102 (41), 14801-14806 [0001]
- **LIU, L. et al.** *Cell*, 2004, vol. 116, 617-628 [0001]
- **YURY VLADIMIROV et al.** NO-hemoglobin may be a light-sensitive source of nitric oxide both in solution and in red blood cells. *JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY*, 01 December 2000, vol. 59 (1-3), 115-122 [0006]

专利名称(译)	测量血液中结合的和结合的一氧化氮的量		
公开(公告)号	EP2170157B1	公开(公告)日	2016-09-07
申请号	EP2008794495	申请日	2008-07-15
[标]申请(专利权)人(译)	杜克大学		
申请(专利权)人(译)	杜克大学		
当前申请(专利权)人(译)	杜克大学		
[标]发明人	STAMLER JONATHAN S ANGELO MICHAEL		
发明人	STAMLER, JONATHAN, S. ANGELO, MICHAEL		
IPC分类号	A61B5/00		
CPC分类号	G01N33/84 A61B5/0059 A61B5/1405 A61B5/14546 A61B5/150022 A61B5/150251 A61B5/150343 A61B5/412 G01N27/416 Y10T436/177692		
优先权	60/935121 2007-07-26 US		
其他公开文献	EP2170157A1 EP2170157A4		
外部链接	Espacenet		

摘要(译)

通过在血液样品中引入低功率电磁辐射束以释放一氧化氮气体，溶解释放的一氧化氮气体并电化学检测溶解的一氧化氮的量来确定血液样品中作为亚硝酰基铁存在的组合的一氧化氮或一氧化氮的量。加油站。




FIG. 1




FIG. 2